Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $2.5 million.

  • Cytek Biosciences' Other Non-Current Liabilities rose 1876.47% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 1876.47%. This contributed to the annual value of $2.4 million for FY2024, which is 275.61% down from last year.
  • Per Cytek Biosciences' latest filing, its Other Non-Current Liabilities stood at $2.5 million for Q3 2025, which was up 1876.47% from $2.5 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Other Non-Current Liabilities high stood at $2.5 million for Q3 2025, and its period low was $737000.0 during Q3 2021.
  • For the 5-year period, Cytek Biosciences' Other Non-Current Liabilities averaged around $1.8 million, with its median value being $1.8 million (2023).
  • As far as peak fluctuations go, Cytek Biosciences' Other Non-Current Liabilities soared by 9497.96% in 2022, and later crashed by 1212.86% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' Other Non-Current Liabilities stood at $1.2 million in 2021, then soared by 31.81% to $1.6 million in 2022, then soared by 53.18% to $2.4 million in 2023, then fell by 2.76% to $2.4 million in 2024, then increased by 6.56% to $2.5 million in 2025.
  • Its Other Non-Current Liabilities was $2.5 million in Q3 2025, compared to $2.5 million in Q2 2025 and $2.4 million in Q1 2025.